Top

International Ophthalmology

Published in:

01-03-2020 | Glaucoma | Original Paper

Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs

Authors: Chang Ho Yoon, Hyun Ju Lee, Hye Youn Park, Hyungsuk Kim, Mee Kum Kim, Jin Wook Jeoung, Joo Youn Oh

Published in: International Ophthalmology | Issue 3/2020

Abstract

Purpose

To investigate the effects of topical autologous serum application on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs.

Methods

The patients who had corneal epitheliopathy because of preservative-containing anti-glaucoma eye drops were prospectively enrolled. The epitheliopathy was refractory to preservative-free artificial tear treatment. The patients topically applied 20% autologous serum to the eye eight times per day for 1 month. Baseline and one-month change in symptoms and signs were assessed by the Ocular Surface Disease Index (OSDI) questionnaire, tear film break-up time (TFBUT), Schirmer I values, corneoconjunctival staining scores, corneal sensitivity, InflammaDry^® tear immunoassay, and tear cytokine profiles using a bead-based multiplex assay.

Results

A total of ten consecutive patients were enrolled between January and August 2018 and evaluated after one-month treatment with 20% autologous serum eye drops. Significant improvement was observed in symptoms (OSDI scores from 25.5 ± 20.9 to 10.5 ± 12.0; P = .039), TFBUT (from 3.1 ± 1.8 s to 5.4 ± 2.3 s; P = .025), corneoconjunctival staining scores (from 7.7 ± 1.8 to 1.8 ± 1.9 NEI scale; P = .005), corneal sensitivity (from 4.6 ± .9 cm to 5.8 ± .5 cm; P = .013), and metalloproteinase-9 levels (P = .013). There were no significant changes in Schirmer I values and tear cytokine levels on multiplex assays. Treatment-related side effects were not detected.

Conclusions

Topical instillation of 20% autologous serum is an effective treatment for toxic corneal epitheliopathy associated with anti-glaucoma eye drops.

Trial registration number

KCT0003827.

Aguayo Bonniard A, Yeung JY, Chan CC, Birt CM (2016) Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol 12:1279–1289. https://doi.org/10.1080/17425255.2016.1209481 CrossRefPubMed

Perez-Bartolome F, Martinez-de-la-Casa JM, Arriola-Villalobos P, Fernandez-Perez C, Polo V, Garcia-Feijoo J (2017) Ocular surface disease in patients under topical treatment for glaucoma. Eur J Ophthalmol 27:694–704. https://doi.org/10.5301/ejo.5000977 CrossRefPubMed

Anwar Z, Wellik SR, Galor A (2013) Glaucoma therapy and ocular surface disease: current literature and recommendations. Curr Opin Ophthalmol 24:136–143. https://doi.org/10.1097/ICU.0b013e32835c8aba CrossRefPubMed

Geerling G, Maclennan S, Hartwig D (2004) Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol 88:1467–1474. https://doi.org/10.1136/bjo.2004.044347 CrossRefPubMedPubMedCentral

Rauz S, Koay SY, Foot B, Kaye SB, Figueiredo F, Burdon MA, Dancey E, Chandrasekar A, Lomas R (2018) The Royal College of Ophthalmologists guidelines on serum eye drops for the treatment of severe ocular surface disease: executive summary. Eye 32:44–48. https://doi.org/10.1038/eye.2017.208 CrossRefPubMed

Moon J, Ko JH, Yoon CH, Kim MK, Oh JY (2018) Effects of 20% human serum on corneal epithelial toxicity induced by benzalkonium chloride: in vitro and clinical studies. Cornea 37:617–623. https://doi.org/10.1097/ICO.0000000000001475 CrossRefPubMed

Lemp MA (1995) Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J 21:221–232PubMed

Park JY, Kim BG, Kim JS, Hwang JH (2018) Matrix metalloproteinase 9 point-of-care immunoassay result predicts response to topical cyclosporine treatment in dry eye disease. Transl Vis Sci Technol 7:31. https://doi.org/10.1167/tvst.7.5.31 CrossRefPubMedPubMedCentral

Kaufman HE (2013) The practical detection of mmp-9 diagnoses ocular surface disease and may help prevent its complications. Cornea 32:211–216. https://doi.org/10.1097/ICO.0b013e3182541e9a CrossRefPubMed

10.

Oh JY, Choi H, Lee RH, Roddy GW, Ylostalo JH, Wawrousek E, Prockop DJ (2012) Identification of the HSPB4/TLR2/NF-kappaB axis in macrophage as a therapeutic target for sterile inflammation of the cornea. EMBO Mol Med 4:435–448. https://doi.org/10.1002/emmm.201200221 CrossRefPubMedPubMedCentral

11.

Sarkar J, Chaudhary S, Namavari A, Ozturk O, Chang JH, Yco L, Sonawane S, Khanolkar V, Hallak J, Jain S (2012) Corneal neurotoxicity due to topical benzalkonium chloride. Invest Ophthalmol Vis Sci 53:1792–1802. https://doi.org/10.1167/iovs.11-8775 CrossRefPubMedPubMedCentral

12.

Chen W, Zhang Z, Hu J, Xie H, Pan J, Dong N, Liu Z (2013) Changes in rabbit corneal innervation induced by the topical application of benzalkonium chloride. Cornea 32:1599–1606. https://doi.org/10.1097/ICO.0b013e3182a8196f CrossRefPubMed

13.

Semeraro F, Forbice E, Nascimbeni G, Taglietti M, Romano V, Guerra G, Costagliola C (2016) Effect of autologous serum eye drops in patients with sjogren syndrome-related dry eye: clinical and in vivo confocal microscopy evaluation of the ocular surface. In Vivo 30:931–938CrossRef

14.

Bradley JC, Simoni J, Bradley RH, McCartney DL, Brown SM (2009) Time- and temperature-dependent stability of growth factor peptides in human autologous serum eye drops. Cornea 28:200–205. https://doi.org/10.1097/ICO.0b013e318186321e CrossRefPubMed

15.

Hussain M, Shtein RM, Sugar A, Soong HK, Woodward MA, DeLoss K, Mian SI (2014) Long-term use of autologous serum 50% eye drops for the treatment of dry eye disease. Cornea 33:1245–1251. https://doi.org/10.1097/ICO.0000000000000271 CrossRefPubMed

16.

Ziakas NG, Boboridis KG, Terzidou C, Naoumidi TL, Mikropoulos D, Georgiadou EN, Georgiadis NS (2010) Long-term follow up of autologous serum treatment for recurrent corneal erosions. Clin Exp Ophthalmol 38:683–687. https://doi.org/10.1111/j.1442-9071.2010.02304.x CrossRefPubMed

Title: Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs
Authors: Chang Ho Yoon
Hyun Ju Lee
Hye Youn Park
Hyungsuk Kim
Mee Kum Kim
Jin Wook Jeoung
Joo Youn Oh
Publication date: 01-03-2020
Publisher: Springer Netherlands
Keywords: Glaucoma
Cytokines
Published in: International Ophthalmology / Issue 3/2020
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-019-01211-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effects of topical autologous serum on the ocular surface in patients with toxic corneal epitheliopathy induced by anti-glaucoma drugs

Abstract

Purpose

Methods

Results

Conclusions

Trial registration number

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Trial registration number

Please log in to get access to this content

Other articles of this Issue 3/2020

Ophthalmic features and management outcomes of 30 children having Goldenhar syndrome

99mTc-DTPA SPECT/CT provided guide on triamcinolone therapy in Graves’ ophthalmopathy patients

The effect of intraocular lens tilt on visual outcomes in scleral-fixated intraocular lens implantation

Medium-term clinical outcomes following Xen45 device implantation

Effect of topical pilocarpine on refractive surgery outcomes

Incidence of dyschromatopsy in glaucoma